SCM
MGNX icon

Suffolk Capital Management’s MacroGenics MGNX Stock Holding History

Suffolk Capital Management’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-35,488
Closed -$660K – 142
2017
Q1 		$660K Sell
35,488
-23,924
-40% -$462K 0.09% 122
2016
Q4 		$1.21M Buy
59,412
+4,695
+9% +$118K 0.17% 119
2016
Q3 		$1.64M Sell
54,717
-3,293
-6% -$97.9K 0.23% 78
2016
Q2 		$1.57M Sell
58,010
-35,241
-38% -$795K 0.2% 124
2016
Q1 		$1.75M Buy
93,251
+1,617
+2% +$30.8K 0.23% 120
2015
Q4 		$2.84M Buy
91,634
+19,246
+27% +$585K 0.36% 77
2015
Q3 		$1.55M Hold
72,388
– – 0.21% 121
2015
Q2 		$2.75M Sell
72,388
-13,157
-15% -$432K 0.33% 91
2015
Q1 		$2.68M Buy
85,545
+30,545
+56% +$1.04M 0.31% 97
2014
Q4 		$1.93M Buy
+55,000
New +$1.37M 0.23% 119

Other funds holding MGNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Suffolk Capital Management's MGNX Position: Q2 2017 in Review

Suffolk Capital Management sold out of MacroGenics (MGNX) in Q2 2017, closing a stake of 35,488 shares — an estimated $660K sold.

Suffolk Capital Management first reported a position in MGNX in Q4 2014 and held it in 10 quarters. The position peaked at $2.84M in Q4 2015. 113 funds tracked by Wall St. Rank hold MGNX as of Q2 2017.

  • Suffolk Capital Management reported no remaining MacroGenics position as of Q2 2017 after selling out during the quarter.
  • Suffolk Capital Management sold 35,488 MacroGenics shares in Q2 2017, an estimated $660K.
  • Suffolk Capital Management first reported a position in MacroGenics in Q4 2014 and held it in 10 quarters.
  • Suffolk Capital Management's MacroGenics position peaked at $2.84M in Q4 2015.
  • 113 funds tracked by Wall St. Rank held MacroGenics as of Q2 2017.

Based on Suffolk Capital Management's 13F filing for Q2 2017, filed 28 Jul 2017.